May 2012 Archives

Meeting a Hero: President Carter and the Importance of Public/Private Partnerships

| 3 Comments
Strahlman Carter.JPG

How does it feel to meet one of your long-time heroes?

 

I had that opportunity last Friday when I met former US President Jimmy Carter for a 1:1 discussion. I was 20 years old when Carter became President, and I have deeply admired his relentless work for world peace, his contribution to world health, and his values as a human being. He won the Nobel Prize for Peace in 2002, as a tribute to his many achievements.

 

GSK has decades-long history of contributing to improve the healthcare of children and families in the US and abroad, and we've had a long and productive relationship with the Carter Center.

 

In 1996, our company (well actually it was SmithKline Beecham, one of our heritage companies) hosted a dinner to honor President Carter with the Bishop John T. Walker Distinguished Humanitarian Award. At this dinner, we asked President Carter how we could make an impact on health. Key world health leaders had just been informed of albendazole's potential role in interrupting transmission of lymphatic filariasis (LF). Commonly known as elephantiasis, LF is one of the world's leading causes of permanent disability and disfigurement. Subsequent meetings and discussions led to the first agreements for our company to donate albendazole in a campaign to eliminate LF in 1998. 

 

And, as they say, "the rest is history." Over a decade later, GSK has donated more than 2.7 billion doses of albendazole for the elimination of LF. Last year we extended our albendazole donation to help deworm some of the world's poorest children. Intestinal worms impose a huge disease burden among school age children in developing countries, often resulting in growth stunting, anemia, malnutrition and poor school performance. As a result of these donation programs, as well as many other activities, GSK is widely recognized as the leader in our industry for drug donation programs and contribution to global health.

 

President Carter was very welcoming when I walked into the room--I was treated to a warm embrace, and then we took a photograph together. When we sat down to talk, his first words were of thanks and appreciation to GSK for the many years of drug donations and support for global health. "Never has a company been more generous, or more committed, to global health," he said. 

 

With enormous pride, I conveyed appreciation for this acknowledgement, and then went on to describe our ongoing and future efforts in global health.

 

During the 40 minutes that followed, we spoke about many topics, including

·         the Carter Center's contributions to other tropical diseases (guinea worm and onchocerciasis) and its health care worker training program in Ethiopia (in which GSK also participates)

·         the GSK PULSE program, and the possibility of volunteers working on Carter Center programs in the future

·         the Carter Center's hosting the International Force for Disease Eradication, and the invitation for GSK to attend as an observer of these meetings

·         the Carter Center's work and programs in conflict resolution, and a discussion of the applicability of these skills in the developing countries of the world

 

The meeting ended with an invitation to return with colleagues for future discussions, along with President Carter's reiteration of thanks and appreciation to GSK. And another hug! In the hours that followed, I met with senior staff at the Carter Center, for further discussions. And in the weeks ahead, I'll be following up with colleagues within GSK to act on some of these ideas.

 

Public/private partnerships with organizations like the Carter Center are essential in tackling these issues--especially in developing countries. It was a tremendous privilege for me represent GSK--to acknowledge and celebrate what has been achieved thus far, and to explore the possibility of doing more together--for patients and for our world.   

Great Debate Can Lead to Great Advancement

| No Comments

Thumbnail image for barnes 2.jpg

Today is International Museum Day, and it has a special meaning in the Philadephia region, where GSK has a significant presence (we're UK-based, and our US HQ is in North Carolina, but we have offices in Philadelphia--soon moving to the Navy Yard--and its suburbs). Today, the new home of the Barnes Foundation--an astounding collection of art--was officially dedicated. It moved from its original location just outside of Philadelphia, in Merion.

 

Now, this move came with a lot of controversy, because the will of founder, Dr. Albert C. Barnes, had to be broken to move it. Dr. Barnes, who made his fortune through the development of an antiseptic, was a real maverick who collected many modern works of art before others were interested. And he bought in bulk: 181 Renoirs, 69 Cézannes, 59 Matisses (is that a word?), 46 Picassos, 21 Soutines, 18 Rousseaus, 16 Modiglianis, 6 Seurats--all displayed in conversation with African sculptures, modern sculptures by the likes of Lipchitz, early American furniture, as well as decorative and functional objects.

 

Barnes was an interesting guy who had a very personal way of appreciating art--and started the Foundation as an educational institution to teach his approach. The educational component of the Foundation is still its primary focus, and better access to the collection is now made available to the public, while the private classes continue to this day.

 

And that educational focus is why GSK is proud to support the grand opening of the new home of the Barnes Foundation. Art appreciation can take many forms, and is important to society.

 

Personally, I think the new home is a beautiful gift to the city, the region, and the world. It won't please everyone, but some of the most important things in life--art, ideas, scientific advancement, politics, policies--spur great controversy. And out of those discussions come some of the greatest advances for society.

 

Let's keep talking.

Sharing Thoughts on the Value of Values at the World Affairs Council

| 1 Comment
DeirdreConnellyBlog.jpg

This week, I spoke to a group of about 200 business leaders at the World Affairs Council in Philadelphia. The session was headlined as "Business in the 21st Century and the Challenges that Lie Ahead." 

 

I mentioned that, as part of GSK's global management team, I'm fortunate to have a role in helping to manage some weighty issues, ranging from navigating the European debt crisis to making our medicines and vaccines available to those in the developing world. 

 

But I focused most of my comments on issues that are closer to home and of more immediate concern to me.  Specifically, I talked about how we are guided by  our values--transparency, integrity, respect, and a focus on the best interests of patients--in  adapting our business model to a rapidly changing healthcare market and the evolving expectations of those we serve.

 

It's a theme I've addressed before and will happily speak about again because I'm absolutely convinced that operating from a core set of values is essential to good business management and good corporate citizenship. 

 

I pointed out that many industries, such as transportation, energy, electronics, and communications, to name just a few, are managing their way through rapidly changing markets as new technologies emerge and customer expectations evolve.  This is clearly the case in healthcare.

 

But I also pointed out that because we bring life-altering and life-saving medicines to patients, society holds our interactions with our customers to a higher standard.  And it should. 

 

My point was that our customers and our stakeholders need to understand that we are very serious about our responsibility to operate our business based on our core values.  And, that our values-based culture creates a framework and a mindset in which compliance with rules and regulations is not the ceiling, but the floor from which we operate.  As such, those values underpin every decision we make and every action we take. 

 

As I said, I've spoken about this before and I will again, because I believe we must incorporate our values in our daily conduct and decision-making so we can meet the expectations society has for us, and our own expectations for how we fulfill our responsibility to help people do more, feel better and live longer.

Putting Patients First Every Day

| No Comments

What would you do if you were diagnosed with an acute illness and needed immediate treatment, but you couldn't afford to fill your prescription? Or you developed a chronic condition for which effective treatment was available, but you couldn't afford to stay on it?

 

Today there are 44 million people in the US with incomes below the Federal Poverty Level and far more who have trouble paying for healthcare, even if they get help from a government program like Medicare.

 

Even though we know the importance of taking medicines as they are prescribed, financial hardships and lack of prescription coverage often cause patients to go without their medicines, or to stretch their treatment in ways that could jeopardize their health.

 

As a member of the GSK Patient Assistance Team, I am proud to help patients receive their medicines. 

 

GSK has one of the largest patient assistance programs in the industry.  Last year close to half a million patients accessed our medicines, and we fill the equivalent of about 2.7 million 30-day prescription fills provided every year. We offer programs that provide GSK medicines at little or no cost for eligible patients.

 

Beyond the facts and figures, we know our programs make a real difference by the many thank you cards, letters, and calls we receive on a daily basis. We hear regularly from patient assistance enrollees who submit comments like "Your caring and generosity make life more bearable for people like me with medical problems" and "[I] won't give up the fight [against cancer]. So glad you were there when I needed the help."  

 

Recently my team received a thank you with a picture of newborn baby enclosed. It was from a grandmother who received help from our patient assistance program for cancer medicines, and she was thrilled to be alive to witness the birth of her granddaughter! I have the best job in the company managing our patient assistance programs and I am so proud to work for a company like GSK that truly puts the patient first and helps them do more, feel better and live longer!

A parade of causes. The drive to run.

| 2 Comments

Thumbnail image for Thumbnail image for PaulV.JPGIt all started with a little orange pedometer. After several months of taking at least 10,000 steps a day, I decided to "kick it up a notch" and attended a workshop at work that, as cliché as it sounds, changed my life.

The class was Energy for Performance, or 'E4P' as the cool kids call it. It focused on three key areas: nutrition, exercise, and mental approach. But at 54, I really didn't think significant change was in my immediate future.

Oh sure, I used to be in decent shape--I even ran the Philly Marathon in 1987. But that was a few lifetimes ago. A quarter century ago. And many, many cheesesteaks ago. During the E4P class, I got a serious wake-up call in the form of a small printout. Just a piece of paper, with several important numbers--my weight was 193 and my BMI (Body Mass Index) was 32. But it was the word in all caps that really jolted me: OBESE. That was it. Ring! Ring! I made the decision to lose weight, get back into shape, and get healthy.

I started running and joined the fitness center at work (thank you, GSK!). My first day, I laced up my new Asics, strapped on the heart monitor that I received in the E4P class and bolted out the door. It would be my longest run that week--a total of three minutes. That's three minutes straight, without stopping. I kid you not. The next week, I increased my time to four minutes, and each week I increased it by one minute. After five months, I was up to running 60 minutes. It was time. I needed a goal. I had to enter a race.

In my younger days, I loved the Broad Street Run. The 10-miler was a Philly tradition, and the course is flat, and almost downhill. The last time I did the run, the finish line was in JFK Stadium. History note--the stadium, famous for the Live Aid concert, was demolished in 1992. I told you it's been a while. But, in my new-found enthusiasm, I decided to do it again, this past Sunday.

The weather was perfect. The atmosphere was amazing, with strangers, children, Temple University cheerleaders, bands playing music, and hundreds of volunteers passing out Gatorade and water. I even got to high-five ex-Governor and Philly celebrity Ed Rendell. They lined the street with cheering, homemade signs, support, and words of encouragement.

It was that enthusiasm that allowed me to finish in a respectable 90 minutes, crossing the finish line not far from our new building at the Navy Yard that will be completed by the end of the year.

But I was only one of 38,000 stories among the 76,000 shoes beating the asphalt on Sunday morning. There was a much greater cause. Stop diseases. Many were running in memory of loved ones who had died from a multitude of diseases, including cancer, muscle diseases, Alzheimer's, and heart disease.

Some were running in support of loved ones who are suffering now, and many others were running to keep themselves healthy in the hope they never have to suffer. At mile marker number eight, I passed Methodist Hospital, where I was born. I thought of my mom, who passed away six years ago from a truly devastating disease, tuberculosis. It made me proud to work for a company that is trying to eliminate diseases.

With the Navy Yard in sight, I saw a small boy hold up a sign that read, "Worst parade ever." Sorry, but I disagree.

   Follow GSKUS on Twitter
Share this page with:
Twitter Twitter
Facebook Facebook
Digg Digg

About this Archive

This page is an archive of entries from May 2012 listed from newest to oldest.

April 2012 is the previous archive.

June 2012 is the next archive.

Find recent content on the main index or look in the archives to find all content.